Pharmaceutical composition for the treatment of ocular neovascularisation
OwnerHeping XU, Frank DAUTZENBERG +1inventors
InventorsHeping XU, Frank DAUTZENBERG, Madlen WITT
Life of this patent
Estimating the term…
Abstract
The present invention relates to a pharmaceutical composition comprising tacrolimus and a semifluorinated alkane for use in the treatment of ocular neovascularisation.
Claims15
A pharmaceutical composition comprising tacrolimus and a semifluorinated alkane for use in a method of treatment of ocular neovascularisation.
The composition for use of any of the preceding claims, wherein the semifluorinated alkane is a semifluorinated alkane of formula (I)
- CF3(CF2)n(CH2)mCH3 (I)
- wherein n is an integer selected from 2 to 10 and m is an integer selected from 2 to 10.
The composition for use of any of the preceding claims, wherein n is 3 and m is 4 or wherein n is 5 and m is 7.
The composition for use of any of the preceding claims, wherein tacrolimus is present at a concentration of at least 0.01% w/v with respect to the total volume of the composition.
The composition for use of any of the preceding claims, wherein tacrolimus is present at a concentration between about 0.01% w/v and 0.1% w/v with respect to the total volume of the composition.
The composition for use of any of the preceding claims, further comprising ethanol.
The composition for use of any of the preceding claims, wherein the composition is topically applied or intravitreously injected to the eye, preferably topically applied.
The composition for use of any of the preceding claims, wherein the ocular neovascularisation is due to uncontrolled expression of pro-angiogenic factors by inflammatory cells.
The composition for use of any of the preceding claims, wherein the dose of tacrolimus administered to the eye is from about 0.5 to 10 micrograms per dose per eye.
The composition for use according to any of the preceding claims, wherein the composition is in form of a solution.
Dependencies are inferred from the claim text.